TISSUE REPAIR LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.215 AUD | +2.38% |
|
+2.38% | -2.27% |
| 02-29 | Tissue Repair Limited Announces Change of Company Secretary | CI |
| 02-28 | Tissue Repair Ltd Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| Sales 2022 | 172K 114K 156K | Sales 2023 | 972K 645K 883K | Capitalization | 16.33M 10.84M 14.83M |
|---|---|---|---|---|---|
| Net income 2022 | -6M -3.98M -5.45M | Net income 2023 | -4M -2.66M -3.63M | EV / Sales 2022 | -60.1 x |
| Net cash position 2022 | 25.46M 16.9M 23.13M | Net cash position 2023 | 21.4M 14.21M 19.44M | EV / Sales 2023 | -5.22 x |
| P/E ratio 2022 |
-1.82
x | P/E ratio 2023 |
-3.91
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 42.38% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.38% | ||
| 1 week | +2.38% | ||
| Current month | -6.52% | ||
| 1 month | -2.27% | ||
| 3 months | -6.52% | ||
| 6 months | -2.27% | ||
| Current year | -2.27% |
1 week
0.19
0.22
1 month
0.190.24
Current year
0.190.26
1 year
0.190.32
3 years
0.190.83
5 years
0.190.83
10 years
0.190.83
| Managers | Title | Age | Since |
|---|---|---|---|
Cameron Jones
DFI | Director of Finance/CFO | - | - |
Mark Waring
CTO | Chief Tech/Sci/R&D Officer | - | - |
Darryl Reed
COO | Chief Operating Officer | - | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 21-08-12 | |
Tony Charara
FOU | Founder | - | 11-12-31 |
| Director/Board Member | - | 21-10-06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-21 | 0.215 | +2.38% | 17,529 |
| 24-06-19 | 0.21 | -4.55% | 36,014 |
| 24-06-18 | 0.22 | 0.00% | 24,892 |
| 24-06-17 | 0.22 | +4.76% | 183,881 |
| 24-06-14 | 0.21 | -2.33% | 35,272 |
Delayed Quote Australian S.E., June 20, 2024 at 08:53 pm
More quotes
Tissue Repair Limited is an Australia-based Phase 3 advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987, with a secondary focus on commercializing TR Pro+ a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures. Its TR Pro+ product provides a range of benefits that assists damaged skin to heal and maintains skin hydration for a moist healing environment to encourage normal scar formation. The Company is also focused on commercializing its propriety Glucoprime active pharmaceutical ingredient (API) to treat a variety of wounds and skin conditions. Glucoprime is a β-glucan molecule, which is designed to assist skin healing and is delivered topically in a hydrogel formulation.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.27% | 8.62M | |
| +15.19% | 121B | |
| +19.91% | 114B | |
| +8.24% | 23.61B | |
| -19.80% | 20.43B | |
| -16.19% | 16.55B | |
| -13.45% | 16.45B | |
| -44.35% | 15.59B | |
| +66.67% | 15.19B | |
| +2.13% | 13.54B |
- Stock Market
- Equities
- TRP Stock
